뒤로
Onkure Therapeutics Inc (OKUR) 수입
OKUR 주가 차트
OKUR 수입
Onkure Therapeutics Inc
$4.14
9.23%
$0.34
오늘 기준:Mar 31, 16:10:17 GMT-4
최신 수익 결과: Q4 '25
보고됨: 2026-03-12
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
OKUR의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Onkure Therapeutics Inc OKUR의 지난 분기 매출 실적은 어땠나요?
Onkure Therapeutics Inc의 매출 추정치는 얼마인가요?
Onkure Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Onkure Therapeutics Inc는 언제 수익을 보고하나요?
Onkure Therapeutics Inc의 예상 수익은 얼마인가요?
Onkure Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$3.79
시가
$3.7
일일 범위
$3.7 - $4.18
52주 범위
$1.7 - $5.1
거래량
428.4K
평균 거래량
128.0K
배당수익률
--
EPS(TTM)
-4.40
시가총액
$56.5M
OKUR란 무엇인가요?
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company is headquartered in Boulder, Colorado and currently employs 45 full-time employees. The company went IPO on 2021-04-09. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. The company is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. The company is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. The company is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. The company also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.